Severity N/A
Bretylium (Tosylate) Interaction of Bretylium (Tosylate) with Amitriptyline (HCl)
Cimetidine (HCl) Interaction of Cimetidine (HCl) with Amitriptyline (HCl)
Clonidine (HCl) Interaction of Clonidine (HCl) with Amitriptyline (HCl)
Debrisoquine (Sulphate) Interaction of Debrisoquine (Sulphate) with Amitriptyline (HCl)
Alcohol Interaction of Alcohol with Amitriptyline (HCl)
Guanethidine Interaction of Guanethidine with Amitriptyline (HCl)
Noradrenaline (Acid Tartrate) Interaction of Noradrenaline (Acid Tartrate) with Amitriptyline (HCl)
Terfenadine Interaction of Terfenadine with Amitriptyline (HCl)
Procainamide (HCl) Interaction of Procainamide (HCl) with Amitriptyline (HCl)
Enflurane Interaction of Enflurane with Amitriptyline (HCl)
Astemizole Interaction of Astemizole with Amitriptyline (HCl)
Sotalol (HCl) Interaction of Sotalol (HCl) with Amitriptyline (HCl)
Phenytoin (Na) Interaction of Phenytoin (Na) with Amitriptyline (HCl)
Fenfluramine (HCl) Interaction of Fenfluramine (HCl) with Amitriptyline (HCl)
Disopyramide Interaction of Disopyramide with Amitriptyline (HCl)
Bethanidine (Sulphate) Interaction of Bethanidine (Sulphate) with Amitriptyline (HCl)
Adrenaline Interaction of Adrenaline with Amitriptyline (HCl)
Disulfiram Interaction of Disulfiram with Amitriptyline (HCl)
Enflurane Interaction of Enflurane with Amitriptyline (HCl)
Human Insulin Interaction of Human Insulin with Amitriptyline (HCl)
Isoproterenol Interaction of Isoproterenol with Amitriptyline (HCl)
Sulpiride Interaction of Sulpiride with Amitriptyline (HCl)
Furazolidone Interaction of Furazolidone with Amitriptyline (HCl)
Insulin Lispro Interaction of Insulin Lispro with Amitriptyline (HCl)
Levodopa Interaction of Levodopa with Amitriptyline (HCl)
Details: Levodopa serum concentration is reduced by amitriptyline due to slow gastric emptying and increase gastric degradation.
Management: Patient monitor for altered safety and efficacy.
Interaction of Ergotamine (Tartrate) with Amitriptyline (HCl)
Details: reports of serotonin syndrome in patients recieving ergotamine with amitriptyline , imipramine, paroxetine, or sertraline
Interaction of Riboflavin (Vitamin B2) with Amitriptyline (HCl)
Details: Tricyclic antidepressants may reduce levels of riboflavin in the body. In addition to raising levels of the vitamin in the body, taking riboflavin may also improve the effects of these antidepressants
Interaction of Antazoline with Amitriptyline (HCl)
Details: Increased antimuscarinic and sedative effects when antihistamines (e.g Antazoline) given with tricyclic antidepressants (e.g Amitriptyline)
Interaction of Nitroglycerin with Amitriptyline (HCl)
Details: simultaneous use may cause orthostatic hypotension
Interaction of Apraclonidine (HCl) with Amitriptyline (HCl)
Management: Avoid concomitant use.
Interaction of Riluzole with Amitriptyline (HCl)
Details: Amitriptyline (HCl) could decrease the rate of riluzole elimination.
Interaction of Nabilone with Amitriptyline (HCl)
Details: Concurrent use may increase the efficacy of nabilone.
Management: Concurrent use should be avoided, or you may need dosage adjustments or special tests during treatment.
Interaction of Pericyazine with Amitriptyline (HCl)
Details: These drugs shouldnot be taken concurrently without doctors prescription.
Interaction of Phentermine with Amitriptyline (HCl)
Details: Concurrent use may result in high blood pressure.
Interaction of Mazindol with Amitriptyline (HCl)
St.Johns Wort Extract Interaction of St.Johns Wort Extract with Amitriptyline (HCl)
Details: Significant reduction in amitriptyline concentrations were reported with concurrent ingestion of St. Johns wort.
Interaction of Acrosoxacin with Amitriptyline (HCl)
Iproniazid Phosphate Interaction of Iproniazid Phosphate with Amitriptyline (HCl)
Details: Infrequent reports of AMITRIPTYLINE increasing the SEROTONERGIC effect of IPRONIAZID. Potential risk.
Interaction of VORICONAZOLE with Amitriptyline (HCl)
Details: additive QTc prolongation may occur
Management: consider alternate therapy
Interaction of Indacaterol with Amitriptyline (HCl)
Details: prolong the QTc interval
Management: should be monitored closely.
Moderate
Thioridazine (HCl) Interaction of Thioridazine (HCl) with Amitriptyline (HCl)
Details: coadministration of these two drugs can cause increase in plasma concentration of both drugs that result in central nervous system depression,hypotension and prolong QT interval.
Management: Combine use of these drugs should be avoided.
Interaction of Carbamazepine with Amitriptyline (HCl)
Details: Carbamazepine accelerates metabolism of tricyclics (e.g Amitriptyline); reduced plasma concentration by induction of CYP450 enzymes and reduced effects.
Management: Tolerance,patient response,seizure control and monitoring of serum concentration should be done.
Interaction of Fluconazole with Amitriptyline (HCl)
Details: Fluconazole inhibit CYP450 3A4 isoenzyme which decrease Amitriptyline clearance leads to CNS toxicity and prolong QT interval.
Management: Adjust amitriptyline dose and monitor its serum levels.
Interaction of Quinidine with Amitriptyline (HCl)
Details: By inhibting CYP450 3A4 2D6 metabolism quinidine increase serum levels of amitriptyline and both these drugs can prolong QT interval.
Management: This combination should be avoided and monitor patient for drowsiness,confusion,weakness and seizures.
Interaction of Warfarin (Na) with Amitriptyline (HCl)
Details: Amitriptyline may enhance the anticoagulant effect of Warfarin.
Management: Monitor for increased prothrombin times (PT)/toxic effects of Warfarin if Amitriptyline is initiated/dose increased, or decreased effects if Amitriptyline is discontinued/dose decreased.
Interaction of Loprazolam with Amitriptyline (HCl)
Details: Theoretical potential for LOPRAZOLAM increasing the SEDATIVE effect of AMITRIPTYLINE.
Interaction of Oxymorphone with Amitriptyline (HCl)
Details: Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.
Management: During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.